Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Morbid Obesity
Conditions
Morbid Obesity
Trial Timeline
Nov 5, 2017 → Sep 1, 2018
NCT ID
NCT03246386About Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg
Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg is a approved stage product being developed by Merck for Morbid Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT03246386. Target conditions include Morbid Obesity.
What happened to similar drugs?
2 of 4 similar drugs in Morbid Obesity were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03246386 | Approved | Completed |
Competing Products
7 competing products in Morbid Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 43 |
| Rocuronium | Merck | Approved | 43 |
| Placebo + IBI362 | Innovent Biologics | Phase 3 | 47 |
| Supemtek® + Vaxigriptetra® | Sanofi | Phase 3 | 40 |
| Molindone | Supernus Pharmaceuticals | Phase 2 | 29 |
| SPN-810M | Supernus Pharmaceuticals | Phase 1 | 23 |
| SPN-810 + Placebo | Supernus Pharmaceuticals | Phase 2 | 29 |